However, neither medication is FDA-approved specifically for weight loss Wegovy (higher-dose semaglutide) is the FDA-approved version for weight management
Most weight lost with GLP-1-based treatment appears to come from fat, and modest reductions in muscle size do not automatically cause declining strength or function
More energy means more movement
While some changes may be innocuous, others, such as turning the active ingredient in a tablet into an untested nasal spray, could pose greater risks
Their growing use of GLP-1 medications added further pressure, so they partnered with WellDyne to control their pharmacy spend
How It Works Semaglutide acts on GLP-1 receptors in the pancreas, brain, and gut to: Stimulate insulin release only when glucose levels are high Suppress glucagon secretion, lowering hepatic glucose output Slow gastric emptying to reduce post-meal glucose spikes Decrease appetite and promote satiety Although the 3 mg dose has limited metabolic impact, it activates these pathways at a low level to reduce side effects as the dose increases